Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

NCT04826003 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: RO7122290
DRUG: Cibisatamab
DRUG: Obinutuzumab

Sponsor

Hoffmann-La Roche